Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will use Continuous Glucose Monitoring to assess differences in glycemic profiles between vildagliptin and glimepiride.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Glimepiride; Vildagliptin

Criteria

Inclusion Criteria:

• Type 2 diabetes patients on stable metformin

• 18-70 years old

• Willing to perform at least 4 capillary blood glucose tests per day

Exclusion Criteria:

• Type 2 diabetes patients on any other antidiabetic treatment

• Patients listed in other trials

• Patients with significant diabetic organ disease or complications.

Other protocol-defined inclusion/exclusion criteria may apply